SCHEMBL15380745

SCHEMBL15380745

NC(=O)n1cccc1-c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 4/20 0.46
PCSK9 Q8NBP7 1/20 0.43
NQO2 P16083 1/20 0.42
CTSD P07339 1/20 0.41
BACE1 P56817 1/20 0.41
LMNA P02545 2/20 0.39
ACHE P22303 2/20 0.39
BCAT2 O15382 1/20 0.38
CYP3A4 P08684 2/20 0.37
POLB P06746 1/20 0.37
MAPT P10636 1/20 0.37
TSHR P16473 1/20 0.37
CYP2C19 P33261 1/20 0.37
RECQL P46063 1/20 0.37
BLM P54132 1/20 0.37
PMP22 Q01453 1/20 0.37
HSD17B10 Q99714 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
MAP2K1 Q02750 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30668584 0.88 PCSK9 (0.46) PCSK9NQO2CTSDBACE1MAPT
SCHEMBL31460477 0.83 PCSK9 (0.41) PCSK9NQO2CTSDBACE1ACHE
SCHEMBL6178669 0.79 KDM4E (0.46) PARP1BACE1DYRK1BNUDT1
SCHEMBL27917050 0.77 TDP1 (0.40) PARP1PCSK9NQO2LMNACYP3A4
SCHEMBL10483377 0.76 BCAT2 (0.47) PARP1LMNABCAT2TSHRRECQL
SCHEMBL22032554 0.73 KDM4E (0.42) POLBMAPTTSHRHSD17B10L3MBTL1
SCHEMBL20557308 0.73 MAOA (0.46) PARP1LMNAMAPTDYRK1BALDH1A1
SCHEMBL12450000 0.72 HSP90AA1 (0.52) L3MBTL1BCHE
SCHEMBL4904690 0.71 TDP1 (0.43) PARP1LMNAACHECYP3A4POLB
SCHEMBL17881873 0.71 RIPK1 (0.44) PCSK9MAPTTSHRL3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023205249-A1 NICOTINE AND NICOTINIC AGONIST COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF PANCREATITIS AND METHODS OF USING SAME DUKE UNIVERSITY (US) 2023-10-26 WO disclosed
CN-109456324-A New isoindoline or isoquinoline compound, preparation method and the Pharmaceutical composition containing them 法国施维雅药厂 2019-03-12 CN disclosed
US-20150133411-A1 COMPOUNDS WITH TRPV4 ACTIVITY, COMPOSITIONS AND ASSOCIATED METHODS THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-05-14 US disclosed
EP-2847164-A1 COMPOUNDS WITH TRPV4 ACTIVITY, COMPOSITIONS AND ASSOCIATED METHODS THEREOF The University of Utah Research Foundation (US) 2015-03-18 EP disclosed
WO-2013169396-A1 COMPOUNDS WITH TRPV4 ACTIVITY, COMPOSITIONS AND ASSOCIATED METHODS THEREOF THE UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2013-11-14 WO disclosed
CN-101006052-B Pyrrole derivatives as pharmaceutical agents EXELIXIS INC 2013-11-06 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150133411-A1 COMPOUNDS WITH TRPV4 ACTIVITY, COMPOSITIONS AND ASSOCIATED METHODS THEREOF TRPV4, TRPV3, TRPV5 PARP1 3882/4885PCSK9 4353/4885NQO2 1330/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.